Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150618 | 0.84 | RORC (0.33) | RORCTRPA1MEN1KMT2ARAB9A | |
| SCHEMBL4148243 | 0.81 | RORC (0.35) | RORCTRPA1MEN1KMT2ARAB9A | |
| SCHEMBL4160312 | 0.78 | KMT2A (0.37) | RORCTDP1TRPA1MEN1KMT2A | |
| SCHEMBL4142017 | 0.78 | TRPA1 (0.33) | RORCTRPA1MEN1KMT2ARAB9A | |
| SCHEMBL4154118 | 0.77 | L3MBTL1 (0.33) | RORCTDP1TRPA1MEN1KMT2A | |
| SCHEMBL13774520 | 0.75 | MEN1 (0.41) | RORCTDP1TRPA1MEN1KMT2A | |
| SCHEMBL13774583 | 0.74 | RAB9A (0.36) | RORCTDP1TRPA1MEN1KMT2A | |
| SCHEMBL4154199 | 0.72 | RAB9A (0.38) | RORCTDP1MEN1KMT2ARAB9A | |
| SCHEMBL4908707 | 0.72 | IL2 (0.44) | RORCTRPA1 | |
| SCHEMBL4157453 | 0.72 | TRPA1 (0.36) | RORCTDP1TRPA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1937629-A2 | BENZOYLUREA COMPOUNDS AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007046513-A2 | BENZOYLUREA COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | BTK, BRIX1, NFXL1 | RORC 4448/4885TDP1 1690/4885TRPA1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.